RxDoctor Payments Data

Alexandr Galkin

Family · Endwell, NYNPI 1710607080

Payments from drug & device makers

$1,033in general payments, 2019–2025

Across 53 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$266
  • Novo Nordisk$116
  • AstraZeneca$115
  • Phathom Pharmaceuticals, Inc.$83
  • GSK$81
  • Daiichi Sankyo Inc.$55
  • plus $317 from 11 others

What the payments were for

  • Food & beverage$1,033100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,033 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$38,413
Medicare patients
257
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab14$148,283
EliquisApixaban96$87,960
FarxigaDapagliflozin Propanediol25$39,808
OzempicSemaglutide28$30,587
JardianceEmpagliflozin17$28,422
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$21,514
XareltoRivaroxaban14$21,463
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$13,685
Topiramate33$10,927
BelbucaBuprenorphine Hcl12$10,178
Lansoprazole22$5,800
Albuterol Sulfate HfaAlbuterol Sulfate110$4,756
ShingrixVaricella-Zoster Ge/As01b/Pf18$4,027
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$3,636
ArexvyRsvpref3 Antigen/As01e/Pf11$3,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$87,96096 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Arexvy$81$42,70774 claims
AstraZenecaFarxiga$115$39,80825 claims
Novo NordiskOzempic$116$30,58728 claims
AbbVieSynthroid$266$89511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,883 family providers in New York.

Other family in Endwell

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →